Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Apellis Pharmaceuticals (Nasdaq: APLS) has announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 13, 2025, at 9:45 a.m. PT.
The company will provide a live webcast of the conference presentation, which will be accessible through the 'Events and Presentations' page in the 'Investors and Media' section of Apellis' website. For those unable to attend live, a replay of the webcast will remain available for approximately 90 days after the event.
Apellis Pharmaceuticals (Nasdaq: APLS) ha annunciato la sua prossima presentazione alla 43ª Conferenza Annuale della J.P. Morgan Healthcare. La presentazione è programmata per lunedì 13 gennaio 2025, alle 9:45 a.m. PT.
L'azienda fornirà una trasmissione in diretta della presentazione alla conferenza, che sarà accessibile attraverso la pagina 'Eventi e Presentazioni' nella sezione 'Investitori e Media' del sito web di Apellis. Per coloro che non possono partecipare dal vivo, una registrazione della trasmissione rimarrà disponibile per circa 90 giorni dopo l'evento.
Apellis Pharmaceuticals (Nasdaq: APLS) ha anunciado su próxima presentación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. La presentación está programada para el lunes 13 de enero de 2025, a las 9:45 a.m. PT.
La empresa proporcionará una transmisión en vivo de la presentación de la conferencia, que estará disponible a través de la página 'Eventos y Presentaciones' en la sección 'Inversores y Medios' del sitio web de Apellis. Para aquellos que no puedan asistir en vivo, la repetición de la transmisión estará disponible durante aproximadamente 90 días después del evento.
Apellis Pharmaceuticals (Nasdaq: APLS)는 제43회 JP 모건 헬스케어 컨퍼런스에서 발표할 예정이라고 발표했습니다. 발표는 2025년 1월 13일 월요일, 오전 9시 45분 PT로 예정되어 있습니다.
회사는 컨퍼런스 발표의 실시간 웹캐스트를 제공할 예정이며, 이는 Apellis의 웹사이트 '투자자 및 미디어' 섹션의 '이벤트 및 발표' 페이지를 통해 접근할 수 있습니다. 생중계에 참석할 수 없는 분들을 위해, 웹캐스트의 재방송은 이벤트 후 약 90일간 이용 가능할 것입니다.
Apellis Pharmaceuticals (Nasdaq: APLS) a annoncé sa prochaine présentation lors de la 43e Conférence Annuelle de J.P. Morgan Healthcare. La présentation est prévue pour le lundi 13 janvier 2025 à 9h45 PT.
L'entreprise proposera une diffusion en direct de la présentation de la conférence, qui sera accessible via la page 'Événements et Présentations' dans la section 'Investisseurs et Médias' du site web d'Apellis. Pour ceux qui ne peuvent pas assister en direct, une rediffusion de la diffusion sera disponible pendant environ 90 jours après l'événement.
Apellis Pharmaceuticals (Nasdaq: APLS) hat seine kommende Präsentation auf der 43. jährlichen J.P. Morgan Healthcare-Konferenz angekündigt. Die Präsentation ist für Montag, den 13. Januar 2025, um 9:45 Uhr PT geplant.
Das Unternehmen wird einen Live-Stream der Konferenzpräsentation anbieten, der über die Seite 'Veranstaltungen und Präsentationen' im Bereich 'Investoren und Medien' auf der Website von Apellis zugänglich ist. Für diejenigen, die nicht live teilnehmen können, bleibt eine Wiederholung des Webcasts etwa 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT.
The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
When is Apellis Pharmaceuticals (APLS) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors watch Apellis' (APLS) J.P. Morgan Healthcare Conference presentation?
How long will the replay of Apellis' (APLS) J.P. Morgan presentation be available?
Where can I find Apellis' (APLS) J.P. Morgan Conference presentation materials?
